AKTX
Closed
Akari Therapeutics Plc
1.165
-0.005 (-0.43%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 1.1699
Day's Range: 1.16 - 1.18
Send
sign up or login to leave a comment!
When Written:
0.1817
Akari Therapeutics PLC is a biopharmaceutical company focused on developing and commercializing treatments for rare and orphan autoimmune and inflammatory diseases. The company's lead product candidate, Coversin, is a complement C5 inhibitor currently in Phase III clinical trials for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). Akari is also developing other complement inhibitors and protein therapeutics for various indications. The company is headquartered in London, UK, and has operations in the US and Switzerland. Akari Therapeutics PLC is listed on the NASDAQ stock exchange under the ticker symbol "AKTX."
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








